(Q79226809)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035949%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035949%20AND%20SRC:MED&resulttype=core&format=json

chronic renal insufficiency

20 December 2019

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035949%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Bigazzi R

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035949%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Campese VM

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035949%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

language of work or name

English

0 references

publication date

11 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035949%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035949%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035949%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035949%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

2116-2123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035949%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.ki.5001854

20 December 2019

exact match

0 references

cites work

Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Vasoactive hormones and renal sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Understanding the nature of renal disease progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Role of angiotensin II in glomerular injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Role of aldosterone in the remnant kidney model in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Regression of existing glomerulosclerosis by inhibition of aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Plasma aldosterone concentrations in chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Beneficial impact of spironolactone in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Rapid nongenomic effects of aldosterone on the renal vasculature in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Nongenomic renal effects of aldosterone: dependency on NO and genomic actions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Nongenomic vascular action of aldosterone in the glomerular microcirculation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Aldosterone in the development and progression of renal injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Aldosterone: intracellular receptors in human heart

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Effect of a selective aldosterone receptor antagonist in myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Glucocorticoid receptor, mineralocorticoid receptors, 11 beta-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: in situ studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Glucocorticoid- and mineralocorticoid receptors in microglial cells: the two receptors mediate differential effects of corticosteroids.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Plasminogen activator inhibitor-1 and the kidney

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001854

7 January 2021